Showing results (431-440 of 537) with videos related to

Sort By:
Pageof 54
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Rheumatology and Therapy|January 5, 2024
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 YearsChristina Charles-Schoeman, Jon T Giles, Nancy E Lane, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Pharmacology & Therapeutics|June 25, 2021
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safetyFrank Kolbinger, Franco Di Padova, Atul Deodhar, et al.
Annals of the Rheumatic Diseases|April 26, 2012
A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritisEdith Villeneuve, Jackie L Nam, Mary J Bell, et al.
RMD Open|March 25, 2022
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trialsIain B McInnes, Andrew J K Ostor, Philip J Mease, et al.
Postgraduate Medical Journal|March 14, 2013
A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritisEdith Villeneuve, Jackie L Nam, Mary J Bell, et al.
BMJ Open|September 28, 2023
Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritisAlexander Ooms, Hussein Al-Mossawi, Louise Bennett, et al.
Annals of the Rheumatic Diseases|January 31, 2013
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trialIain B McInnes, Joachim Sieper, Jürgen Braun, et al.
The Lancet. Rheumatology|April 30, 2021
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trialArthur G Pratt, Stefan Siebert, Michael Cole, et al.
Pageof 54